SCHEMBL9108360

SCHEMBL9108360

O=C(Cc1cccc(Cl)c1)Oc1ccc(Cl)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.54
CTBP2 P56545 1/20 0.50
RXRA P19793 1/20 0.49
RXRB P28702 1/20 0.49
RXRG P48443 1/20 0.49
MAOA P21397 2/20 0.48
MAOB P27338 2/20 0.48
HTR3E A5X5Y0 1/20 0.47
HTR3B O95264 1/20 0.47
HTR3A P46098 1/20 0.47
HTR3D Q70Z44 1/20 0.47
HTR3C Q8WXA8 1/20 0.47
ALOX5 P09917 1/20 0.47
PIK3CA P42336 1/20 0.47
MRGPRX4 Q96LA9 1/20 0.46
TAAR1 Q96RJ0 1/20 0.46
CA2 P00918 2/20 0.45
CA5A P35218 2/20 0.45
GAA P10253 1/20 0.45
ALOX12 P18054 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9107911 0.89 SMN1; SMN2 (0.51) KMT2ACTBP2RXRARXRBRXRG
SCHEMBL11783599 0.85 KMT2A (0.61) KMT2ATAAR1MEN1ALDH1A1
SCHEMBL22511027 0.84 FFAR1 (0.52) KMT2AALDH1A1
SCHEMBL4673743 0.83 KMT2A (0.71) KMT2ACA2CA5AGAA
SCHEMBL22510800 0.82 HCAR2 (0.49) CTBP2RXRARXRBRXRGTAAR1
SCHEMBL31244291 0.80 CTBP2 (0.56) KMT2ACTBP2RXRARXRBRXRG
Acetamide SCHEMBL27730622 0.78 KMT2A (0.62) KMT2ATAAR1GAAMEN1ALDH1A1
SCHEMBL31225894 0.78 SMN1; SMN2 (0.49) KMT2ACTBP2RXRARXRBRXRG
SCHEMBL6970344 0.78 CTBP2 (0.54) KMT2ACTBP2RXRARXRBRXRG
SCHEMBL378633 0.78 SLC7A5 (0.55) KMT2ACTBP2MAOAMAOBHTR3E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140057952-A1 NOVEL OXADIAZOLE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS ALLERGAN, INC. (US) 2014-02-27 US disclosed
US-8618139-B2 Oxadiazole derivatives as sphingosine 1-phosphate (S1P) receptor modulators ALLERGAN, INC. (US) 2013-12-31 US disclosed
US-20120142739-A1 NOVEL OXADIAZOLE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS ALLERGAN, INC. (US) 2012-06-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140057952-A1 NOVEL OXADIAZOLE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS S1PR3, S1PR1, S1PR2 KMT2A 4217/4885CTBP2 3215/4885RXRA 1944/4885
US-20120142739-A1 NOVEL OXADIAZOLE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS S1PR3, S1PR1, S1PR2 KMT2A 4217/4885CTBP2 3215/4885RXRA 1944/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.